Last reviewed · How we verify
pembrolizumab; vorinostat
At a glance
| Generic name | pembrolizumab; vorinostat |
|---|---|
| Also known as | KEYTRUDA; ZOLINZA |
| Sponsor | UNICANCER |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma (PHASE1)
- Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (PHASE1)
- Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PHASE2)
- Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma (PHASE1)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pembrolizumab; vorinostat CI brief — competitive landscape report
- pembrolizumab; vorinostat updates RSS · CI watch RSS
- UNICANCER portfolio CI